Published in Cancer Vaccine Week, September 5th, 2005
"PA is a natural triterpenoid known to inhibit the phospholipase A2 (PLA2) family of arachidonic acid (AA)-producing enzymes. PLA2 is elevated in prostatic adenocarcinoma and conversion of AA to prostaglandins leads to AKT pro-survival activity," investigators in the United States reported.
"In this study, we investigated the effect of PA on the growth of human prostate cancer cells. PA significantly reduced cell proliferation and induced apoptosis in a dose- and time-dependent fashion, with androgen-insensitive DU145 prostate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.